1) 岩間毅夫, 他 : 遺伝性腫瘍の概念と分類. 三木義男編, 最新遺伝性腫瘍・家族性腫瘍研究と遺伝カウンセリング, メディカルドゥ, 大阪, 2016, p.20-23.
2) Funato M, et al : Characteristics of Li-Fraumeni syndrome in Japan : A review study by the special committee of JSHT. Cancer Sci, 112 : 2821-2834, 2021.
3) Vogelstein B, et al : Genetic alterations during colorectal-tumor development. N Engl J Med, 319 : 525-532, 1988.
4) Knudson AG Jr : Mutation and cancer : Statistical study of retinoblastoma. Proc Natl Acad Sci USA, 68 : 820-823, 1971.
5) Friend SH, et al : A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature, 323 : 643-646, 1986.
6) Toguchida J, et al : Complete genomic sequence of the human retinoblastoma susceptibility gene. Genomics, 17 : 535-543, 1993.
7) Banno K, et al : Epimutation and cancer : A new carcinogenic mechanism of Lynch syndrome (Review). Int J Oncol, 41 : 793-797, 2012.
8) Albuquerque C, et al : The 'just-right' signaling model : APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet, 11 : 1549-1560, 2002.
9) Kumamoto K, et al : Germline and somatic mutations of the APC gene in papillary thyroid carcinoma associated with familial adenomatous polyposis : Analysis of three cases and a review of the literature. Oncol Lett, 10 : 2239-2243, 2015.
10) 大腸癌研究会編 : 遺伝性大腸癌診療ガイドライン 2020年版. 金原出版, 東京, 2020.
11) 日本遺伝性乳癌卵巣癌総合診療制度機構編 : 遺伝性乳癌卵巣癌 (HBOC) 診療ガイドライン 2021年版. 第2版, 金原出版, 東京, 2021.
12) Blair VR, et al : Hereditary diffuse gastric cancer : Updated clinical practice guidelines. Lancet Oncol, 21 : 386-397, 2020.
13) van der Post RS, et al : Hereditary diffuse gastric cancer : Updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet, 52 : 361-374, 2015.
14) Umar A, et al : Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst, 96 : 261-268, 2004.
15) Matsubayashi H, et al : Familial pancreatic cancer : Concept, management and issues. World J Gastroenterol, 23 : 935-948, 2017.
16) Brune KA, et al : Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst, 102 : 119-126, 2010.
17) Van Dyke AL, et al : Family history of cancer and risk of biliary tract cancers : Results from the biliary tract cancers pooling project. Cancer Epidemiol Biomarkers Prev, 27 : 348-351, 2018.
18) Ball MW, et al : Inherited kidney cancer syndromes. Curr Opin Urol, 29 : 334-343, 2019.
19) Lui ST, et al : Genetic testing in kidney cancer patients : Who, When, and How? Eur Urol Focus, 5 : 973-976, 2019.
20) Carter BS, et al : Hereditary prostate cancer : Epidemiologic and clinical features. J Urol, 150 : 797-802, 1993.
21) 深堀能立, 他 : 遺伝性・家族性前立腺癌. 日本臨牀, 74 (増刊号 3) : 47-51, 2016.
22) Castro E, et al : Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol, 31 : 1748-1757, 2013.
23) NCCN : NCCN Clinical practice in Oncology (NCCN Guideleines(R)). Genetic/Familial High-Risk Assessment : Breast and Ovarian. Version 2, 2018.
24) Hirasawa A, et al : Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget, 8 : 112258-112267, 2017.